Marksans Pharma Limited Overview
Pro stress-test →Marksans Pharma is an India-based company engaged in research, manufacturing and marketing of generic pharmaceutical formulations in global markets. The company's portfolio comprises OTC products (74% of FY24 revenue) including pain management, cough and cold, and digestive remedies, plus prescription products (26%) covering cardiovascular, CNS, and anti-diabetic drugs.
Strategic Profile
Pro stress-test →The company's manufacturing capacity has reached 26 billion units per year, a fourfold increase over several years. Marksans aims for ₹4,000 crore revenue in 2-3 years with projected 20% growth in the US market. The company has recently formed wholly owned subsidiaries in Ireland and Canada to expand its pharmaceutical business internationally.
Competitive Landscape
Pro stress-test →Marksans Pharma's peers include Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Torrent Pharmaceuticals Ltd, Cipla Ltd, Dr Reddys Laboratories Ltd, Zydus Lifesciences Ltd, and Mankind Pharma Ltd. Marksans differentiates through strong OTC presence and expanding manufacturing scale across regulated markets.
Industry Context
Marksans Pharma Limited operates in Pharmaceutical Formulations - Generic & OTC.
Key facts
Founded: 1992 · Headquarters: Mumbai, India · Revenue: ₹2,094.8Cr (9M FY26) · Market cap: $0.95B